Effect of immunophenotyping on prognosis of multiple myeloma patients treated with bortezomib as main treatment
10.3760/cma.j.issn.1009-9921.2018.08.003
- VernacularTitle: 免疫表型对以硼替佐米为主方案治疗的多发性骨髓瘤患者预后的影响
- Author:
Jingjing ZHOU
1
;
Xianqi FENG
1
;
Shumin NIE
2
;
Xuemei WANG
1
;
Junxia HUANG
1
;
Yan GAO
1
;
Wei WANG
1
;
Fanjun MENG
1
;
Hongguo ZHAO
1
;
Chunting ZHAO
1
Author Information
1. Department of Hematology, the Affiliated Hospital of Qingdao University, Qingdao 266555, China
2. Department of Neurology, the Affiliated Hospital of Qingdao University, Qingdao 266555, China
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Immunophenotyping;
Bortezomib;
Prognosis
- From:
Journal of Leukemia & Lymphoma
2018;27(8):459-463
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of immunophenotyping on prognosis of multiple myeloma (MM) patients treated with bortezomib regimen as main treatment.
Methods:Seventy-six MM patients in the Department of Hematology in the Affiliated Hospital of Qingdao University from January 2012 to January 2017 were retrospectively analyzed. The effects of the expressions of CD45, CD56 and other factors on progression free survival (PFS) and overall survival (OS) in MM patients treated with bortezomib-containing regimen were also analyzed.
Results:Univariate analysis showed that statistical differences of the median PFS (12 months vs. 19 months, P < 0.001) and median OS (19 months vs. 23 months, P= 0.001) were significant in the group of CD45 positive and negative of MM patients; the median PFS (14 months vs. 21 months, P= 0.014) and median OS (16 months vs. 25 months, P= 0.026) for MM patients with hemoglobin (Hb) < 100 g/L and Hb ≥ 100 g/L were statistically significant; the median PFS (13 months vs. 18 months, P= 0.004) and median OS (14 months vs. 24 months, P= 0.008) for MM patients with albumin (ALB) < 35 g/L and ALB ≥ 35 g/L were statistically significant. The median PFS time and the median OS time in female MM patients were shorter than those in male MM patients (13 months vs. 19 months, P= 0.008; 16 months vs. 25 months, P= 0.008). Multivariate analysis showed that female and CD45 positive were the independent poor prognostic factors for PFS and OS in MM patients (P < 0.05).
Conclusion:CD45 positive and female are important prognostic factors for MM patients treated with bortezomib regimen as main treatment.
